Poolbeg Pharma Secures European Patent for POLB 001 Targeting Severe Influenza and Cancer Immunotherapy Side Effects
Key Insights
Poolbeg Pharma (search) received European Patent Office (search) approval for its POLB 001 treatment, a selective p38 MAP kinase (search) inhibitor targeting severe influenza (search) and cancer (search) immunotherapy-induced cytokine release syndrome (search).
The patent strengthens Poolbeg's global intellectual property portfolio and enhances the drug's appeal to potential partners in a market opportunity estimated at over $10 billion.
POLB 001 has potential to address significant unmet medical needs by preventing life-threatening cytokine release syndrome (search), potentially expanding cancer (search) immunotherapy access from specialist centers to community hospitals.
Poolbeg Pharma (search) has secured a significant milestone in its intellectual property strategy with the European Patent Office (search) granting its European Immunomodulator II patent application for POLB 001, a treatment targeting severe influenza (search) and cancer (search) immunotherapy-induced complications.
The clinical-stage biopharmaceutical company announced that the patent covers the use of POLB 001, a potent and selective p38 MAP kinase (search) inhibitor. The treatment has demonstrated strong potential across multiple disease areas, including the prevention and treatment of cancer (search) immunotherapy-induced Cytokine Release Syndrome (search) (CRS), representing a market opportunity estimated at over $10 billion, as well as severe influenza (search) treatment.
Expanding Global IP Portfolio
The patent grant represents another step in Poolbeg's strategy to build a comprehensive worldwide intellectual property portfolio. The company's IP strategy encompasses patents covering the use of p38 MAPK (search) inhibitors in patients with severe influenza (search) and for the prevention and treatment of CRS caused by cancer (search) immunotherapy.
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma (search), emphasized the significance of this development: "This patent grant from the European Patent Office (search) highlights the strong progress we continue to make in developing and strengthening our IP portfolio for POLB 001 across multiple disease indications. This further enhances the value and attractiveness of POLB 001 for potential partners."
Addressing Critical Medical Needs
POLB 001 holds potential to address significant unmet needs affecting patients and healthcare systems globally. The drug's ability to prevent life-threatening cytokine release syndrome (search) could transform cancer (search) immunotherapy administration by making treatments safer and potentially expanding their use from centralized specialist cancer centers to community hospitals.
This expansion could increase the number of patients able to receive life-saving cancer (search) immunotherapies, thereby broadening the market opportunity for these treatments. The company positions POLB 001 as having the potential to transform the cancer immunotherapy landscape by addressing one of the field's most serious complications.
Strategic Positioning
The European patent grant further strengthens Poolbeg's robust intellectual property portfolio, enhancing POLB 001's value and appeal to potential partners. The company continues to focus on partnering its high-value programs that target large markets and address critical unmet medical needs.
Poolbeg Pharma (search), which trades on AIM under the ticker POLB, maintains its core focus on transforming the cancer (search) immunotherapy field while developing treatments for multiple therapeutic areas. The company's approach centers on developing patient-friendly therapies that can address significant healthcare challenges across various disease indications.